Core Insights - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, received approval from the NMPA for the innovative drug Relmapirazin Injection, marking a significant milestone in the company's product portfolio [1] - The drug is designed to be used in conjunction with MediBeacon's TGFR device to assess patients' glomerular filtration rate (GFR), addressing a critical clinical need in chronic kidney disease (CKD) management [1][2] - The approval of Relmapirazin Injection and the TGFR device signifies a successful collaboration between Huadong Medicine and MediBeacon, enhancing the company's position in the renal health market [2][3] Product and Market Potential - The TGFR device, which has already received FDA approval in the U.S., is expected to improve the efficiency of clinical assessments of kidney function, addressing the high prevalence of CKD globally [2][3] - Chronic kidney disease poses a significant public health challenge, with a global median prevalence of 9.5% and a mortality rate of 2.4%, highlighting the urgent need for effective screening and intervention [2] - Huadong Medicine plans to leverage its commercialization strengths to ensure rapid market penetration of the TGFR device and Relmapirazin Injection in China, aiming to benefit a large patient population [4]